# Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Source: https://onco.cc/trials/nct07214779/  
OnCo record `nct07214779` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing INCB123667 in ovarian cancer, now recruiting.

## Summary

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is a phase 3 interventional study registered as NCT07214779, led by Incyte with ENGOT Foundation and GOG Foundation, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression. Planned enrolment is 466 participants (estimated). The study started in 2025-12-09 and primary completion is expected in 2028-11-15. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: MAESTRA 2
- Tags: ctgov-ingest
- Registry id: NCT07214779
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Sponsor: Incyte
- Enrolled: 466

## Sources

- ClinicalTrials.gov NCT07214779: https://clinicaltrials.gov/study/NCT07214779

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [INCB123667](https://onco.cc/drugs/incb123667/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct07214779.json